Shanghai Shen Lian Biomedical Corp (688098) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shanghai Shen Lian Biomedical Corp (688098) has a cash flow conversion efficiency ratio of 0.015x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥21.52 Million ≈ $3.15 Million USD) by net assets (CN¥1.42 Billion ≈ $207.93 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 688098 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Shanghai Shen Lian Biomedical Corp - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Shanghai Shen Lian Biomedical Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Shanghai Shen Lian Biomedical Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanghai Shen Lian Biomedical Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Phoenix Property Investment Co Ltd
SHG:600716
|
0.015x |
|
PVA TePla AG
XETRA:TPE
|
0.002x |
|
Tae Kwang Corporation
KQ:023160
|
0.012x |
|
Beijing Bewinner Communications Co Ltd
SHE:002148
|
-0.005x |
|
Akis Gayrimenkul Yatirim Ortakligi AS
IS:AKSGY
|
0.015x |
|
ZH.JIN.ENV.HLDG DL-00001
F:3UG
|
N/A |
|
Hexagon Purus As
OL:HPUR
|
-1.040x |
|
Nepes Corporation
KQ:033640
|
0.041x |
Annual Cash Flow Conversion Efficiency for Shanghai Shen Lian Biomedical Corp (2013–2025)
The table below shows the annual cash flow conversion efficiency of Shanghai Shen Lian Biomedical Corp from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see 688098 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥1.40 Billion ≈ $204.71 Million |
CN¥33.08 Million ≈ $4.84 Million |
0.024x | -62.28% |
| 2024-12-31 | CN¥1.43 Billion ≈ $208.61 Million |
CN¥89.36 Million ≈ $13.08 Million |
0.063x | +2579.52% |
| 2023-12-31 | CN¥1.51 Billion ≈ $220.53 Million |
CN¥3.53 Million ≈ $515.90K |
0.002x | -61.47% |
| 2022-12-31 | CN¥1.50 Billion ≈ $219.04 Million |
CN¥9.09 Million ≈ $1.33 Million |
0.006x | -90.08% |
| 2021-12-31 | CN¥1.47 Billion ≈ $215.54 Million |
CN¥90.12 Million ≈ $13.19 Million |
0.061x | -23.54% |
| 2020-12-31 | CN¥1.40 Billion ≈ $204.32 Million |
CN¥111.73 Million ≈ $16.35 Million |
0.080x | +90.53% |
| 2019-12-31 | CN¥1.28 Billion ≈ $187.49 Million |
CN¥53.81 Million ≈ $7.87 Million |
0.042x | -71.15% |
| 2018-12-31 | CN¥831.94 Million ≈ $121.74 Million |
CN¥121.13 Million ≈ $17.73 Million |
0.146x | +7.20% |
| 2017-12-31 | CN¥549.27 Million ≈ $80.38 Million |
CN¥74.61 Million ≈ $10.92 Million |
0.136x | +31.73% |
| 2016-12-31 | CN¥465.47 Million ≈ $68.11 Million |
CN¥48.00 Million ≈ $7.02 Million |
0.103x | +6.05% |
| 2015-12-31 | CN¥317.41 Million ≈ $46.45 Million |
CN¥30.86 Million ≈ $4.52 Million |
0.097x | -77.84% |
| 2014-12-31 | CN¥241.57 Million ≈ $35.35 Million |
CN¥105.98 Million ≈ $15.51 Million |
0.439x | +177.50% |
| 2013-12-31 | CN¥327.59 Million ≈ $47.94 Million |
CN¥51.79 Million ≈ $7.58 Million |
0.158x | -- |
About Shanghai Shen Lian Biomedical Corp
Shanghai Shen Lian Biomedical Corporation engages in the research, development, production, and sale of veterinary biological products in China. It develops synthetic peptide vaccines to treat foot-and-mouth diseases. The company was founded in 2001 and is headquartered in Shanghai, China.